Here are the latest G-BA decisions from the G-BA meeting held on 4 December 2025 on the early benefit assessments of Opdivo in two new indications.
A database of all previous G-BA resolutions is available in my store.
Opdivo (Nivolumab); new indication:
- unresectable or advanced hepatocellular carcinoma, first-line, in combination with ipilimumab – Additional benefit not proven in both subgroups
- non-small cell lung cancer, PD-L1 expression ≥ 1%, neoadjuvant and adjuvant therapy, monotherapy or in combination with platinum-based chemotherapy – Additional benefit not proven
Follow me on Instagram to never miss the latest G-BA decisions: